Trials / Unknown
UnknownNCT01635686
Comparison the Safety and Pharmacokinetic Characteristics of DWP422 25 mg With Those of ENBREL 25MG PFS INJ. After Subcutaneous Injection in Healthy Male Volunteers
A Randomized, Double-blind, Single-dosing, Crossover Study to Compare the Safety and Pharmacokinetic Characteristics of DWP422 25 mg With Those of ENBREL 25MG PFS INJ. After Subcutaneous Injection in Healthy Male Volunteers
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 38 (estimated)
- Sponsor
- Daewoong Pharmaceutical Co. LTD. · Industry
- Sex
- Male
- Age
- 20 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study was to compare the safety and pharmacokinetic characteristics of DWP422 25 mg with those of ENBREL 25MG PFS INJ. after subcutaneous injection in healthy male volunteers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DWP422 25mg | |
| DRUG | ENBREL 25MG PFS INJ. |
Timeline
- Start date
- 2012-09-01
- Primary completion
- 2013-06-01
- Completion
- 2013-06-01
- First posted
- 2012-07-09
- Last updated
- 2012-07-26
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT01635686. Inclusion in this directory is not an endorsement.